Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Cisplatin + Fluorouracil |
| Synonyms | |
| Therapy Description | |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Cisplatin | Platinol | CDDP | Chemotherapy - Platinum 7 | Platinol (cisplatin) is a platinum based chemotherapeutic, which is FDA approved for bladder, ovarian, and testicular cancers (NCI Drug Dictionary). |
| Fluorouracil | Adrucil | 5-FU|5-Fluorouracil | Chemotherapy - Antimetabolite 14 | Adrucil (fluorouracil) is an antimetabolite chemotherapeutic agent, which interferes with DNA and RNA synthesis thereby preventing cancer cell growth and is FDA approved for colorectal, breast, stomach, and pancreatic cancer (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02494583 | Phase III | Capecitabine Cisplatin + Fluorouracil Pembrolizumab | Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062) | Completed | 0 | |
| NCT03281369 | Phase Ib/II | Atezolizumab + Cobimetinib Atezolizumab + Cisplatin + Fluorouracil + Tiragolumab Atezolizumab + Cisplatin + Fluorouracil Atezolizumab + Cobimetinib + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Linagliptin Atezolizumab + PEGPH20 Atezolizumab + BKT140 Paclitaxel + Ramucirumab Cisplatin + Fluorouracil Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Tiragolumab | A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) | Active, not recruiting | USA | ISR | GBR | ESP | AUS | 2 |
| NCT03675737 | Phase III | Capecitabine + Oxaliplatin Capecitabine + Oxaliplatin + Pembrolizumab Cisplatin + Fluorouracil + Pembrolizumab Cisplatin + Fluorouracil | Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) | Active, not recruiting | USA | TUR | POL | NZL | ITA | ISR | IRL | HUN | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BRA | AUS | ARG | 14 |
| NCT04747054 | Phase III | Pembrolizumab + Radiotherapy Pembrolizumab Carboplatin + Fluorouracil Cisplatin + Fluorouracil | Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers (PembroMetaRT) | Recruiting | FRA | 0 |
| NCT02051868 | Phase II | Carboplatin + Paclitaxel Cisplatin + Fluorouracil | International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel (InterAACT) | Unknown status | USA | GBR | AUS | 0 |
| NCT00588770 | Phase III | Bevacizumab Cisplatin + Docetaxel Cisplatin + Fluorouracil Carboplatin + Docetaxel Carboplatin + Fluorouracil | Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Active, not recruiting | USA | 2 |
| NCT03221426 | Phase III | Capecitabine + Cisplatin Capecitabine + Cisplatin + Pembrolizumab Cisplatin + Fluorouracil + Pembrolizumab Cisplatin + Fluorouracil | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) | Active, not recruiting | USA | POL | LVA | LTU | ITA | ISR | GBR | FRA | EST | DEU | CAN | BRA | BEL | 11 |
| NCT03189719 | Phase III | Cisplatin + Fluorouracil Cisplatin + Fluorouracil + Pembrolizumab | First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590) | Completed | USA | TUR | ROU | GBR | FRA | ESP | DNK | DEU | CAN | BRA | AUS | ARG | 14 |
| NCT04550260 | Phase III | Cisplatin + Fluorouracil Capecitabine + Cisplatin Capecitabine + Cisplatin + Durvalumab Cisplatin + Durvalumab + Fluorouracil | Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC (KUNLUN) | Active, not recruiting | USA | TUR | POL | FRA | ESP | CAN | BRA | BEL | 8 |
| NCT06019130 | Phase II | Cisplatin + Fluorouracil Cisplatin + Gemcitabine Nivolumab | Nivolumab in Children and Adults With Nasopharyngeal Carcinoma (NPC-Nivo) | Recruiting | DEU | 0 |
| NCT02205047 | Phase II | Capecitabine + Cisplatin Cisplatin + Fluorouracil + Pertuzumab + Trastuzumab Cisplatin + Fluorouracil Cisplatin + Fluorouracil + Trastuzumab Capecitabine + Cisplatin + Trastuzumab Capecitabine + Cisplatin + Pertuzumab + Trastuzumab | Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma (INNOVATION) | Active, not recruiting | NOR | NLD | ITA | GBR | FRA | EST | ESP | DEU | CHE | BEL | 3 |
| NCT03777657 | Phase III | Capecitabine + Oxaliplatin Cisplatin + Fluorouracil Capecitabine + Oxaliplatin + Tislelizumab Cisplatin + Fluorouracil + Tislelizumab | Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma | Completed | USA | TUR | POL | ITA | GBR | FRA | ESP | 6 |
| NCT03727061 | Phase II | Cisplatin + Fluorouracil Carboplatin + Fluorouracil Pembrolizumab Cetuximab Nivolumab | Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer | Active, not recruiting | USA | 0 |
| NCT05661188 | Phase II | Atezolizumab + Tiragolumab Cisplatin + Fluorouracil | Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS) (TIRANUS) | Recruiting | ESP | 0 |
| NCT03143153 | Phase III | Ipilimumab + Nivolumab Cisplatin + Fluorouracil Cisplatin + Fluorouracil + Nivolumab | A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin (CheckMate 648) | Active, not recruiting | USA | TUR | ROU | POL | ITA | GBR | FRA | ESP | DNK | CZE | CAN | BRA | AUT | AUS | ARG | 12 |
| NCT04210115 | Phase III | Cisplatin + Fluorouracil + Pembrolizumab Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Cisplatin + Fluorouracil | Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975) | Active, not recruiting | USA | TUR | ROU | ITA | HUN | GBR | FRA | EST | DNK | DEU | CZE | CAN | BRA | BEL | ARG | 12 |
| NCT03748134 | Phase III | Cisplatin + Fluorouracil Cisplatin + Fluorouracil + Sintilimab Cisplatin + Paclitaxel Cisplatin + Paclitaxel + Sintilimab | Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma (ORIENT-15) | Completed | USA | HUN | FRA | ESP | BEL | AUS | 1 |
CKB BOOST